Terry Smith’s ADMA Biologics ADMA Stock Holding History

Terry Smith’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8M	Hold	1,649,493	–	–	0.1%	39
2026 Q1	$14.9M	Sell	1,649,493 -452,561	-22%	-$7.14M	0.12%	32
2025 Q4	$38.3M	Buy	+2,102,054	New	+$35.4M	0.22%	35

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Terry Smith's ADMA Position: Q2 2026 in Review

Terry Smith held its ADMA Biologics (ADMA) position steady in Q2 2026 at 1,649,493 shares worth $13.8M. The position accounts for 0.1% of the portfolio, ranked #39.

Terry Smith first reported a position in ADMA in Q4 2025 and has held it in 3 quarters since. The position peaked at $38.3M in Q4 2025. 321 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Terry Smith held 1,649,493 shares of ADMA Biologics worth $13.8M as of Q2 2026.
Terry Smith left its ADMA Biologics share count unchanged in Q2 2026.
ADMA Biologics made up 0.1% of Terry Smith's portfolio in Q2 2026, its #39 holding.
Terry Smith first reported a position in ADMA Biologics in Q4 2025 and has held it in 3 quarters since.
Terry Smith's ADMA Biologics position peaked at $38.3M in Q4 2025.
321 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Fundsmith LLP's 13F filing for Q2 2026, filed 14 Aug 2026.